» Articles » PMID: 33854974

Myeloid-Derived Suppressor Cells in Immune Microenvironment Promote Progression of Esophagogastric Junction Adenocarcinoma

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Apr 15
PMID 33854974
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Adenocarcinoma of the esophagogastric junction (AEG) is a fatal disease. Accumulating evidence indicates that, for a comprehensive understanding of AEG, studies should be conducted not only to investigate tumor cells, but also the tumor microenvironment (TME). In this study, we collected AEG patient data from The Cancer Genome Atlas, and used the CIBERSORT algorithm to analyze tumor-infiltrating immune cell profiles. The levels of CD8 T cells and M0 and M2 macrophages were relatively high in AEG tissues. M2 macrophages were abundant in G3 tumors, and neutrophils were associated with poor prognosis. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immunosuppressive cells which share a similar origin to neutrophils and macrophages. We further analyzed the levels of MDSCs in AEG patients and healthy donors (HD) using flow cytometry. MDSC levels were elevated at tumor sites, with polymorphonuclear MDSCs (PMN-MDSCs) being the predominant subtype. Circulating MDSCs partly represented cells at the tumor site. We observed that PMN-MDSC levels at tumor sites were positively correlated with advanced staging, low grade, lymph node metastasis, and HER2 status. Immunohistochemistry and immunofluorescence analyses indicated that activation of the STAT3 and NF-κB pathways in MDSCs may be a potential mechanism for cancer progression. Our studies provided a comprehensive perspective involving tumor-infiltrating immune cells, and detailed insights into the proportion of MDSCs in AEG and their clinical significance. Together, these findings may improve our current understanding of cancer progression involving tumor-infiltrating immune cells in the TME.

Citing Articles

Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs.

Shi X, Pang S, Zhou J, Yan G, Gao R, Wu H Mol Cancer. 2024; 23(1):52.

PMID: 38461272 PMC: 10924381. DOI: 10.1186/s12943-024-01968-2.


Prognostic stratification based on the levels of tumor-infiltrating myeloid-derived suppressor cells and PD-1/PD-L1 axis in locally advanced rectal cancer.

Lim Y, Koh J, Choi M, Kim S, Chie E Front Oncol. 2022; 12:1018700.

PMID: 36387259 PMC: 9641101. DOI: 10.3389/fonc.2022.1018700.


Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Kudo-Saito C, Boku N, Hirano H, Shoji H Front Immunol. 2022; 13:1009701.

PMID: 36211375 PMC: 9539086. DOI: 10.3389/fimmu.2022.1009701.


Feedback loop between fatty acid transport protein 2 and receptor interacting protein 3 pathways promotes polymorphonuclear neutrophil myeloid-derived suppressor cells-potentiated suppressive immunity in bladder cancer.

Shi X, Pang S, Zhou J, Yan G, Sun J, Tan W Mol Biol Rep. 2022; 49(12):11643-11652.

PMID: 36169895 DOI: 10.1007/s11033-022-07924-x.


The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma.

Zheng S, Liu B, Guan X Front Oncol. 2022; 12:911285.

PMID: 35814365 PMC: 9257257. DOI: 10.3389/fonc.2022.911285.


References
1.
Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View

2.
Najafi M, Goradel N, Farhood B, Salehi E, Shabani Nashtaei M, Khanlarkhani N . Macrophage polarity in cancer: A review. J Cell Biochem. 2018; 120(3):2756-2765. DOI: 10.1002/jcb.27646. View

3.
Mace T, Ameen Z, Collins A, Wojcik S, Mair M, Young G . Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 2013; 73(10):3007-18. PMC: 3785672. DOI: 10.1158/0008-5472.CAN-12-4601. View

4.
Reyes C, Teller S, Muckenhuber A, Konukiewitz B, Safak O, Weichert W . Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Clin Cancer Res. 2019; 26(1):220-231. DOI: 10.1158/1078-0432.CCR-19-1864. View

5.
Wang L, Chang E, Wong S, Ong S, Chong D, Ling K . Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2012; 190(2):794-804. DOI: 10.4049/jimmunol.1202088. View